RU2438190C1 - Method of pharmacological correction of ischemic tissues survival rate in reduced blood circulation environment - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: for tissue ischemia correction, in the reduced blood circulation environment an isolated pedicle skin flap is simulated in a laboratory animal. On the first, third and fifth experimental days, recombinant erythropoietin 50 IU/kg is injected subcutaneously.

EFFECT: method provides correction of the survival rate values of ischemic tissue of an isolated skin flap with a greater area of healthy tissue in 1,5 times in comparison with control animals, including due to the effective doses developed for such experiment and regiment of the drug.

1 tbl

Description

The invention relates to medicine, in particular to experimental pharmacology, and can be used to correct ischemia.

Erythropoietin is a glycoprotein hormone that is synthesized in the cortical layer of the kidneys. Its well-known features are displayed in the title. Recently, after the discovery of erythropoietin receptors on many organs, including on the endothelium, increased interest in its non-hematopoietic functions. It is known that in small doses, the hormone does not affect hematopoiesis.

Closest to the claimed solution is to study the effect of the macrolide preparation of azithromycin on the survival of a skin flap on a leg described by E. Chernomortseva et al., patent for invention RU 2283116 C2.

However, this decision does not evaluate the effect of recombinant erythropoietin on the survival of a leg flap.

The objective of the invention is to develop a method for improving the survival rate of ischemic tissues (isolated skin flap on the leg) in conditions of reduced blood circulation, including the use of recombinant erythropoietin.

The objective is achieved in that for the purpose of pharmacologically correcting the survival rates of ischemic tissues in the conditions of reduced blood circulation to a laboratory animal, which on the second day of the experiment simulates an isolated skin flap on a leg, recombinant erythropoietin at a dose of 50 IU / kg is administered subcutaneously on the first, third and fifth days experiment.

The method is as follows.

The experiments were conducted on male Wistar white rats weighing 200-220 g. Modeling of the skin flap was carried out under anesthesia (chloral hydrate 50 mg / kg ip) on the second day of the experiment. Retreating 1 cm from the xiphoid process, a skin flap 1 cm is cut out - the base, 4 cm - length, is isolated in a plastic bag, the edges of the skin are sutured with a continuous suture. Assessment of the survival of the skin flap is carried out on the sixth day of the experiment by measuring the area of healthy tissue. The survival of a skin flap was evaluated in the group with a simulated skin flap and in the group of animals that underwent pharmacological correction by subcutaneous administration of recombinant erythropoietin at a dose of 50 IU / kg on the first, third and fifth days of the experiment.

When statistical data processing is calculated, the average value, the standard deviation. Differences are considered significant at p <0.05.

Concrete example

The experiments were performed on male Wistar white rats weighing 200-220 g. The experimental animals were divided into the following groups:

1. Control (n = 10);

2. Using recombinant erythropoietin (n = 10).

Animals of both groups had a skin flap modeled on the second day of the experiment. Under anesthesia (chloral hydrate 50 mg / kg ip), departing 1 cm from the xiphoid process, a skin flap was cut 1 cm - base, 4 cm - length, isolated in a plastic bag, the edges of the skin were sutured with a continuous suture. In the second group of animals, correction was made by subcutaneous administration of recombinant erythropoietin at a dose of 50 IU / kg on the first, third, and fifth days of the experiment.

Assessment of the survival of the skin flap was performed on the sixth day of the experiment, measuring the area of healthy tissue.

The results of the evaluation of the survival of the skin flap are presented in the table.

Survival indices of an isolated skin flap on a stalk on the 5th day after modeling (6th day of the experiment) (M ± m) Group (n = 10) Area of healthy tissue in cm % Isolated skin flap (control) 1.59 ± 0.03 39.75 Isolated skin flap + recombinant erythropoietin 2.5 ± 0.15 * 62.5 Note: * - p≤0.05 when compared with the control group

In the control group, the area of healthy tissue on the fifth day was 1.59 ± 0.03 cm, i.e. 39.75% of the initial area of the skin flap. In the group of animals that underwent correction with recombinant erythropoietin, the area of healthy tissue increased to 2.5 ± 0.15 cm, i.e. 62.5% (see table).

Thus, the obtained results allow us to state an improvement in the survival rate of ischemic tissues in the conditions of reduced blood circulation under the influence of recombinant erythropoietin by 1.57 times compared with the control group.

Claims (1)

A method for pharmacologically correcting survival rates of ischemic tissues under reduced blood circulation, including modeling an isolated skin leg flap, characterized in that recombinant erythropoietin is administered subcutaneously to a laboratory animal at a dose of 50 IU / kg on the first, third and fifth days of the experiment.